BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 163,000 shares of BioCryst common stock on October 30, 2020 as inducements material to each employee entering into employment with BioCryst.

Organogenesis Holdings Inc. announced that the latest research on its PuraPly® AM, Affinity®, Apligraf®, NuShield® and Dermagraft® product lines will be presented at the 2020 Symposium on Advanced Wound Care Fall Virtual meeting, held November 4-6.

Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 40,950 shares of common stock and 11,650 restricted stock units to be distributed among nine new employees with a grant date of Nov. 2, 2020.

Co-Diagnostics, Inc. announced that following the discovery of an incorrectly recorded expense in the period ending June 30, 2020, Management will be amending its June 30, 2020 Form 10-Q by filing Amendment No. 1 on Form 10-Q/A with the Securities and Exchange Commission to show an increase in basic and diluted net income per common share of $0.08 as of and for the three and six months ended June 30, 2020.

Align Technology, Inc. announced the opening of its 2021 Research Award Program to support clinical and scientific dental research in universities across the globe.

Akumin Inc., announced that it completed its private offering of $400 million of aggregate principal amount of 7.00% senior secured notes due 2025.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, November 5, 2020.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on its development programs before the market opens on November 9, 2020.

Tiger Woods, Rory Sabbatini, and Brian Gay are all Centinel Spine patient spokespeople that have prolonged their PGA careers and accomplished new milestones after spine surgery with the company’s devices